MetaCap

Ascendis Pharma A/S (ASND) vs BridgeBio Pharma (BBIO)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Ascendis Pharma A/S (ASND) has outperformed BridgeBio Pharma (BBIO) over the past year, gaining 20.1% versus a gain of 11.6%. Over five years, BBIO leads with a +92.2% price change compared with +75.7% for ASND. Ascendis Pharma A/S is the larger company by market cap ($16.58 billion vs $14.81 billion), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ASND+20.07%BBIO+11.63%
+34%+13%-9%
Nov 21, 20251 yearNov 20, 2026
ASND+69.83%BBIO+78.26%
+111%+8%-94%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ASND versus BBIO key metrics
MetricASNDBBIO
Share price$252.73$76.03
Market cap$16.58B$14.81B
1-day change-1.26%-2.75%
YTD return+18.52%-0.60%
1-year return+20.07%+11.63%
5-year return+75.73%+92.24%
P/E ratio (TTM)16.62—
Forward P/E20.47—
EPS (TTM)$15.21$-3.03
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$502.08M
Revenue growth (YoY)—+126.26%
Net income (latest FY)—$-732.94M
Gross margin—95.82%
Operating margin—-104.25%
Net margin—-145.98%
52-week high$282.15$93.42
52-week low$188.08$62.50
Distance from 52-week high-10.43%-18.61%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+24.95%+40.73%
Average volume750.65K2.67M
Shares outstanding65.60M194.80M
Employees1,1891,081
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Ascendis Pharma A/S

ASND stock →

Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism.

Health Care · Biotechnology: Pharmaceutical Preparations · 1,189 employees

About BridgeBio Pharma

BBIO stock →

BridgeBio Pharma, Inc., a biopharmaceutical company, discovers, develops, and delivers medicines for patients with genetic diseases. The company offers Attruby, a next-generation oral small molecule near-complete TTR stabilizer for the treatment of cardiomyopathy of wild-type or transthyretin-mediated amyloidosis (ATTR-CM); Fosdenopterin, an intravenous formulation of synthetic cyclic pyranopterin monophosphate for the treatment of molybdenum cofactor deficiency under the NULIBRY brand name; and low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 clinical stage or the treatment of children with achondroplasia and hypochondroplasia.

Health Care · Biotechnology: Pharmaceutical Preparations · 1,081 employees

ASND vs BBIO FAQ

Which is bigger, Ascendis Pharma A/S or BridgeBio Pharma?

Ascendis Pharma A/S (ASND) is larger, with a market capitalization of $16.58B compared with $14.81B for BridgeBio Pharma (BBIO).

Which stock has performed better over the past year, ASND or BBIO?

ASND returned +20.07% over the past 12 months, compared with +11.63% for BBIO (price return, excluding dividends). Past performance does not predict future results.

Are Ascendis Pharma A/S and BridgeBio Pharma in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons